1. Home
  2. Analysis
  3. Adempas
  4. Raynaud-s-phenomenon

Adempas and Raynaud's phenomenon - a phase IV clinical study of FDA data

Summary:

Raynaud's phenomenon is reported as a side effect among people who take Adempas (riociguat), especially for people who are female, 60+ old, also take Letairis, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Raynaud's phenomenon when taking Adempas. It is created by eHealthMe based on reports of 29,726 people who have side effects when taking Adempas from the FDA, and is updated regularly.

What is Adempas?

Adempas has active ingredients of riociguat. eHealthMe is studying from 29,741 Adempas users. Check the latest studies of Adempas.

What is Raynaud's phenomenon?

Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas) is found to be associated with 635 drugs and 995 conditions by eHealthMe. Check the latest studies of Raynaud's phenomenon.

On May, 11, 2026

29,726 people reported to have side effects when taking Adempas.
Among them, 12 people (0.04%) have Raynaud's phenomenon.

Could Adempas cause Raynaud's phenomenon?

Among these 12 people:

What is the gender of people who have Raynaud's phenomenon when taking Adempas? *

  • female: 100 %
  • male: 0.0 %

What is the age of people who have Raynaud's phenomenon when taking Adempas? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 9.09 %
  • 50-59: 0.0 %
  • 60+: 90.91 %

What are other drugs people take besides Adempas? *

  1. Letairis: 5 people, 41.67%
  2. Xarelto: 4 people, 33.33%
  3. Opsumit: 4 people, 33.33%
  4. Revatio: 2 people, 16.67%
  5. Macitentan: 2 people, 16.67%
  6. Amitriptyline Hydrochloride: 1 person, 8.33%
  7. Amlodipine: 1 person, 8.33%
  8. Apixaban: 1 person, 8.33%
  9. Celexa: 1 person, 8.33%
  10. Clonidine: 1 person, 8.33%

What are other side effects people have besides Raynaud's phenomenon? *

  1. Hypotension (abnormally low blood pressure): 3 people, 25.00%
  2. Diarrhea: 3 people, 25.00%
  3. Localised Infection (infection at the single location): 2 people, 16.67%
  4. Dyspnea Exertional: 2 people, 16.67%
  5. Dyspnea (difficult or laboured breathing): 2 people, 16.67%
  6. Nausea And Vomiting: 2 people, 16.67%
  7. Hospitalisation: 2 people, 16.67%
  8. Dizziness: 2 people, 16.67%
  9. Peripheral Swelling: 2 people, 16.67%
  10. Fatigue (feeling of tiredness): 2 people, 16.67%

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 9 people, 75.00%
  2. Pulmonary Hypertension (increase in blood pressure in the lung artery): 4 people, 33.33%
  3. Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Adempas and have Raynaud's phenomenon?

- Check whether Raynaud's phenomenon is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adempas:

Raynaud's phenomenon treatments and more:

How severe was Raynaud's phenomenon and when was it recovered:

Expand to all the drugs that have ingredients of riociguat:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Adempas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Raynaud's phenomenon:

Browse all the conditions that are associated with Raynaud's phenomenon:

How the study uses the data?

The study uses data from the FDA. It is based on riociguat (the active ingredients of Adempas) and Adempas (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.